Hai-Fei Xiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hai-Fei Xiang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Chun-Lian Zhou
Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University
1 shared publicationFeng Lin
Department of Anesthesiology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou 317000, China
1 shared publication- Feng Lin
Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University
1 shared publication Guo Yu
Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University
1 shared publicationJian-Bin Cao
Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University
1 shared publicationJun-Ming Chen
Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University
1 shared publication
Latest Publications
- Open Access
- 27 October 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2568985
Efficacy and safety of remimazolam for sedation during gynaecologic procedures: a systematic review and meta-analysis
The efficacy of remimazolam compared to propofol for sedation during gynaecologic procedures remains unknown, due to the increased severity of pain associated with these procedures. Therefore, a systematic review and meta-analysis was conducted to address this issue. The protocol has been registered with PROSPERO, number CRD42024511475. Medline/PubMed, Cochrane Library, Embase, Scopus and Web of Science were searched to identify randomized controlled trials (RCTs) covering the period up to 10 January 2025. The primary outcomes comprised the success rate of sedation and the incidence of body movement. Secondary outcomes included recovery time and incidence of adverse effects (i.e. hypotension, bradycardia, respiratory depression, postoperative nausea and vomiting (PONV), dizziness, hiccup and injection pain). Nine RCTs (1129 patients) were included in this meta-analysis. There were no significant differences for the success rate of sedation (RR = 0.98, 95% confidence interval (CI) 0.96-1.00) or the incidence of body movement (RR = 1.03, 95% CI 0.49-2.14). Remimazolam had a lower incidence of adverse effects, including hypotension (RR = 0.21, 95% CI 0.11-0.41), bradycardia (RR = 0.12, 95% CI 0.02-0.97), respiratory depression (RR = 0.30, 95% CI 0.15-0.61), injection pain (RR = 0.06, 95% CI 0.02-0.17) and dizziness (RR = 0.29, 95% CI 0.10-0.82). However, remimazolam increased the incidence of hiccup (RR = 10.16, 95% CI 2.48-41.61). No significant differences were found regarding the recovery time (MD = 1.58, 95% CI -0.20 to 3.35) or the incidence of PONV (RR = 0.68, 95% CI 0.15-3.05). In gynaecologic procedures, remimazolam has comparable efficacy to propofol in the success rate of sedation and the incidence of body movement, while exhibiting superior respiratory and cardiovascular safety profiles. These findings should be cautiously generalized to other populations, and warrant further validation.
- 27 October 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2568985
Open AccessEfficacy and safety of remimazolam for sedation during gynaecologic procedures: a systematic review and meta-analysis
The efficacy of remimazolam compared to propofol for sedation during gynaecologic procedures remains unknown, due to the increased severity of pain associated with these procedures. Therefore, a systematic review and meta-analysis was conducted to address this issue. The protocol has been registered with PROSPERO, number CRD42024511475. Medline/PubMed, Cochrane Library, Embase, Scopus and Web of Science were searched to identify randomized controlled trials (RCTs) covering the period up to 10 January 2025. The primary outcomes comprised the success rate of sedation and the incidence of body movement. Secondary outcomes included recovery time and incidence of adverse effects (i.e. hypotension, bradycardia, respiratory depression, postoperative nausea and vomiting (PONV), dizziness, hiccup and injection pain). Nine RCTs (1129 patients) were included in this meta-analysis. There were no significant differences for the success rate of sedation (RR = 0.98, 95% confidence interval (CI) 0.96-1.00) or the incidence of body movement (RR = 1.03, 95% CI 0.49-2.14). Remimazolam had a lower incidence of adverse effects, including hypotension (RR = 0.21, 95% CI 0.11-0.41), bradycardia (RR = 0.12, 95% CI 0.02-0.97), respiratory depression (RR = 0.30, 95% CI 0.15-0.61), injection pain (RR = 0.06, 95% CI 0.02-0.17) and dizziness (RR = 0.29, 95% CI 0.10-0.82). However, remimazolam increased the incidence of hiccup (RR = 10.16, 95% CI 2.48-41.61). No significant differences were found regarding the recovery time (MD = 1.58, 95% CI -0.20 to 3.35) or the incidence of PONV (RR = 0.68, 95% CI 0.15-3.05). In gynaecologic procedures, remimazolam has comparable efficacy to propofol in the success rate of sedation and the incidence of body movement, while exhibiting superior respiratory and cardiovascular safety profiles. These findings should be cautiously generalized to other populations, and warrant further validation.
- 12 November 2024
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 493, 117155
ROS responsive nanozyme loaded with STING silencing for the treatment of sepsis-induced acute lung injury
- 12 November 2024
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 493, 117155
ROS responsive nanozyme loaded with STING silencing for the treatment of sepsis-induced acute lung injury